-transparent.png){kind=logo}
The inhibition by somatostatin (SRIF) of basal and arginine-stimulated glucagon, insulin, and glucose levels was compared with that obtained when SRIF was preceded by alpha-adrenergic blockade with phentolamine. No noteworthy differences were observed, except that the characteristic rebound of insulin upon discontinuation of SRIF was significantly lower with phentolamine (P less than 0.01). These results indicate that inhibition of basal and arginine-stimulated glucagon and insulin secretion by SRIF in man is not mediated through activation by alpha-adrenergic receptors.
Related Publications
J K Schmitt, and
M Lorenzi, and
J E Gerich, and
N V Bohannon, and
J H Karam, and
P H Forsham
January 1980,
Pharmacological research communications,
J K Schmitt, and
M Lorenzi, and
J E Gerich, and
N V Bohannon, and
J H Karam, and
P H Forsham
August 1985,
Clinical endocrinology,
J K Schmitt, and
M Lorenzi, and
J E Gerich, and
N V Bohannon, and
J H Karam, and
P H Forsham
January 1973,
Nephron,
J K Schmitt, and
M Lorenzi, and
J E Gerich, and
N V Bohannon, and
J H Karam, and
P H Forsham
September 1977,
British heart journal,
J K Schmitt, and
M Lorenzi, and
J E Gerich, and
N V Bohannon, and
J H Karam, and
P H Forsham
April 1976,
Endocrinology,
J K Schmitt, and
M Lorenzi, and
J E Gerich, and
N V Bohannon, and
J H Karam, and
P H Forsham
May 1965,
Circulation,
J K Schmitt, and
M Lorenzi, and
J E Gerich, and
N V Bohannon, and
J H Karam, and
P H Forsham
August 1977,
Metabolism: clinical and experimental,
J K Schmitt, and
M Lorenzi, and
J E Gerich, and
N V Bohannon, and
J H Karam, and
P H Forsham
September 1968,
The Journal of pharmacology and experimental therapeutics,
J K Schmitt, and
M Lorenzi, and
J E Gerich, and
N V Bohannon, and
J H Karam, and
P H Forsham
February 1974,
Chest,
J K Schmitt, and
M Lorenzi, and
J E Gerich, and
N V Bohannon, and
J H Karam, and
P H Forsham
August 1978,
Metabolism: clinical and experimental,
